Study Title and Description
Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA.
Key Questions Addressed
|3||In adult renal transplants, how do immunosuppressive regimens designed to reduce or eliminate exposure to CNI toxicity compare with each other and with full-dose CNI regimens for health outcomes? AND How does the type of induction agent (including when no induction is used) and the use of concurrent immunosuppressive agents affect outcomes of regimens that reduce or eliminate CNI exposure?|
Primary Publication Information
|Title||Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA.|
|Author||Rostaing L., Hertig A., Albano L., Anglicheau D., Durrbach A., Vuiblet V., Moulin B., Merville P., Hazzan M., Lang P., Touchard G., Hurault deLigny B., Quéré S., Di Giambattista F., Dubois YC., Rondeau E.|
|Country||Department of Nephrology, Dialysis and Transplantation, Hôpital de Rangueil, Toulouse, France.|
Pubmed ID: 25808994
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Comparative Effectiveness of Regimens
Results & Comparisons
No Results found.